
Our Vision
Cyprotex Discovery’s vision is to provide, in partnership with our customers in drug discovery and development, the highest quality, fastest turnaround and most cost-effective ADMET and pharmacokinetic data to the pharmaceutical industry.
As a pure service business, we aspire to be a leading edge technology business in the provision of ADMET screening services and in silico prediction to our customers which will translate into the discovery of more effective medicines.
Our Ambition
• To exceed our customers' expectations in the provision of our services
• To maintain our position as the leading ADMET / PK outsourced service provider to the pharmaceutical industry
• To focus on our core deliverables of highly reproducible data in the fastest turnaround time and at the most cost–effective price to our customers
• To invest in and further develop our unique automated platform and information management systems
• To improve the recognition of the Cyprotex and Cyprotox brand worldwide
• To expand our customer base and deepen the relationships of our existing clients

Genomic ADME - gADME™
Cyprotex's proprietary gADME™ system can alert you to genetic variations in drug metabolism, allowing for personalised doses, drug rescue and repositioning.
Learn more about gADME
In vitro Micronucleus Test
Cyprotex now offers the in vitro micronucleus test for genotoxicity assessment using an automated, high content screening method for improved detection and reliability.
Learn more about our in vitro MNT service
Drug Transporters
Cyprotex provides a full range of drug-transporter studies as recommended by the ITC white paper and EMA guidelines.
Learn more about transporters

By Dr. Katya Tsaioun, Chief Scientific Officer, Cyprotex
Wiley & Sons, March 2011


